Literature DB >> 25196766

Diabetic macular edema.

Fabio Patelli1, Paolo Radice, Enrico Giacomotti.   

Abstract

Diabetic macular edema (DME) is one of the most common causes of visual loss in patients with diabetes mellitus. Many patients continue to lose vision despite laser photocoagulation and medical therapies. The two major categories of medications currently used to treat DME are corticosteroids and anti-VEGF agents. The vitreous has been implicated as a cause of macular edema in people with diabetes via several mechanical and physiologic mechanisms, all of which are postulated to lead to increased vascular permeability. Vitrectomy can release the mechanical traction on the macula and increase oxygenation with subsequent reduction in DME. Early vitrectomy even in nontractional DME results in significant macular thinning and may lead to rapid improvement in vision with long-term stabilization. Unfortunately, a randomized trial pitting vitrectomy against the methods currently employed has not yet been performed.
© 2014 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2014        PMID: 25196766     DOI: 10.1159/000360463

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  7 in total

1.  An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy.

Authors:  Fernanda Pacella; Maria Rosaria Romano; Paolo Turchetti; Giovanna Tarquini; Anna Carnovale; Antonella Mollicone; Alessandra Mastromatteo; Elena Pacella
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

2.  Visual impairment and blindness in type 2 diabetics: Ife-Ijesa diabetic retinopathy study.

Authors:  O H Onakpoya; B A Kolawole; A O Adeoye; B O Adegbehingbe; O Laoye
Journal:  Int Ophthalmol       Date:  2015-11-04       Impact factor: 2.031

3.  The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.

Authors:  In Hwan Hong; Wonseok Choi; Jae Ryong Han
Journal:  Jpn J Ophthalmol       Date:  2020-01-03       Impact factor: 2.447

Review 4.  Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics.

Authors:  Aniruddha Agarwal; Mohamed K Soliman; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Pharmgenomics Pers Med       Date:  2014-12-12

5.  Expression of Long Non-Coding RNA (lncRNA) SNHG5 in Patients with Refractory Diabetic Macular Edema and Its Regulatory Mechanism.

Authors:  Junwen He; Zhang Rui; Jing Gao; Yanhong Chen; Yanzi Li; Tao Xu; Shan Wang
Journal:  Med Sci Monit       Date:  2022-01-10

6.  The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results.

Authors:  Mert Simsek; Mehmet Citirik; Serdar Ozates; Kemal Tekin; Dilara Ozkoyuncu
Journal:  Beyoglu Eye J       Date:  2020-02-19

7.  Expression of microRNA-155-5p in patients with refractory diabetic macular edema and its regulatory mechanism.

Authors:  Junwen He; Rui Zhang; Shan Wang; Lu Xie; Chengfeng Yu; Tao Xu; Yanzi Li; Tao Yan
Journal:  Exp Ther Med       Date:  2021-07-08       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.